Research programme: anthrax-ricin vaccine - Soligenix

Drug Profile

Research programme: anthrax-ricin vaccine - Soligenix

Alternative Names: Ricin-anthrax vaccine - Soligenix; RiVax™ plus VeloThrax™

Latest Information Update: 27 Aug 2014

Price : $50

At a glance

  • Originator Soligenix
  • Class Anthrax vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anthrax; Ricin poisoning

Most Recent Events

  • 19 Aug 2014 Preclinical trials in Ricin poisoning (Prevention) in USA (unspecified route)
  • 19 Aug 2014 Preclinical trials in Anthrax (Prevention) in USA (unspecified route)
  • 19 Aug 2014 Research programme: anthrax-ricin vaccine - Soligenix is available for licensing in World as of 19 Aug 2014. www.soligenix.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top